These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 18726663)

  • 1. [Pathophysiology and therapy of benign prostatic hyperplasia].
    Sampson N; Madersbacher S; Berger P
    Wien Klin Wochenschr; 2008; 120(13-14):390-401. PubMed ID: 18726663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benign prostatic hyperplasia: age-related tissue-remodeling.
    Untergasser G; Madersbacher S; Berger P
    Exp Gerontol; 2005 Mar; 40(3):121-8. PubMed ID: 15763388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
    Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options.
    Inamura S; Terada N
    Int J Urol; 2024 Sep; 31(9):968-974. PubMed ID: 38934050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
    O'Leary MP
    Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign prostatic hyperplasia - progress in pathophysiology and management.
    Dobrek Ł; Thor PJ
    Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review on the Timing of Surgical Intervention for Benign Prostatic Enlargement (BPE).
    Stoddard MD; Cho A; Te AE; Chughtai B
    Curr Urol Rep; 2020 Nov; 21(12):64. PubMed ID: 33230722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of benign prostatic hyperplasia.
    Pinheiro LC; Martins Pisco J
    Tech Vasc Interv Radiol; 2012 Dec; 15(4):256-60. PubMed ID: 23244720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.
    MacDonald D; McNicholas TA
    Drugs; 2003; 63(18):1947-62. PubMed ID: 12930164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia.
    Thiyagarajan M
    Pharmacology; 2002 Jul; 65(3):119-28. PubMed ID: 12037374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
    De Nunzio C; Presicce F; Tubaro A
    Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Rademaker A; Lloyd GL; Gann P
    J Urol; 2005 Oct; 174(4 Pt 1):1327-433. PubMed ID: 16145413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.
    Madersbacher S; Sampson N; Culig Z
    Gerontology; 2019; 65(5):458-464. PubMed ID: 30943489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
    Kulig K; Malawska B
    Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.